Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivoceranib in Recurrent or Metastatic Olfactory Neuroblastoma
NCT06308575Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of Rivoceranib in olfactory neuroblastoma (ONB), sponsored by University of Texas MD Anderson Cancer Center. Planned start Nov 2024; status: withdrawn.
02
Drugs
Rivoceranib
03
Conditions
olfactory neuroblastoma (ONB)
Beyond the preview
Go deeper on NCT06308575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06308575.